Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population.
Acta Pharmacol Sin
; 36(5): 535-43, 2015 May.
Article
in En
| MEDLINE
| ID: mdl-25891088
ABSTRACT
The field of pharmacogenomics was initiated in the 1950s and began to thrive after the completion of the human genome project 10 years ago. Thus far, more than 100 drug labels and clinical guidelines referring to pharmacogenomic biomarkers have been published, and several key pharmacogenomic markers for either drug safety or efficacy have been identified and subsequently adopted in clinical practice as pre-treatment genetic tests. However, a tremendous variation of genetic backgrounds exists between different ethnic groups. The application of pharmacogenomics in the Chinese population is still a long way off, since the published guidelines issued by the organizations such as US Food and Drug Administration require further confirmation in the Chinese population. This review highlights important pharmacogenomic discoveries in the Chinese population and compares the Chinese population with other nations regarding the pharmacogenomics of five most commonly used drugs, ie, tacrolimus, cyclosporine A, warfarin, cyclophosphamide and azathioprine.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pharmacogenetics
/
Asian People
/
Precision Medicine
/
Immunosuppressive Agents
/
Anticoagulants
Type of study:
Guideline
Limits:
Humans
Country/Region as subject:
Asia
Language:
En
Journal:
Acta Pharmacol Sin
Journal subject:
FARMACOLOGIA
Year:
2015
Document type:
Article
Affiliation country:
China